BET bromodomain inhibitor

BET bromodomain inhibitor is an orally active BET inhibitor with an IC50 of 14 nM against BRD4 (1) . BET bromodomain inhibitor can inhibit the proliferation of tumor cells and induce cell cycle arrest and apoptosis. BET bromodomain inhibitor can be used in the research of tumors[1][2].

Product Specifications

CAS Number

[1505453-59-7]

UNSPSC

12352005

Hazard Statement

H302-H315-H319-H335

Target

Apoptosis; Epigenetic Reader Domain

Type

Reference compound

Related Pathways

Apoptosis; Epigenetics

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/BET_bromodomain_inhibitor.html

Purity

99.53

Solubility

DMSO : ≥ 100 mg/mL

Smiles

O=C(N)C[C@@H]1N=C(C2=CC=C(Cl)C=C2)C3=CC(C4=CN(C)N=C4)=CC=C3C5=C1ON=C5C

Molecular Formula

C24H20ClN5O2

Molecular Weight

445.90

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

References & Citations

[1]Andrew Ryan CONERY, et al. EXPRESSION LEVELS OF BCL-xL, BCL2, BCL-w, AND BAD AND CANCER THERAPIES. WO2015153871A2. 2015-10-08.|[2]Romero FA, et al. Disrupting Acetyl-Lysine Recognition: Progress in the Development of Bromodomain Inhibitors. J Med Chem. 2016 Feb 25;59 (4) :1271-98.